According to our previous study, short-term intensive insulin therapies by CSII can improve β-cell function by eliminating glucotoxicity in newly diagnosed patients. It's interesting that young patients seems to recover better than old patients. The purpose of this study is to clarify the effect and mechanism of age on T2DM remission from short-term intensive insulin therapies. An observation of 160 patients with newly diagnosed T2DM (n=160, 103 male, aged 50±10 ys,HbA1C 11±2.1%) after 2-week therapy was studied remission rate. They were divided to young group (age<50ys)(n=77) and old group (n=83). After 1-year of the termination of intensive therapy, there are obviously more remission patients in the young group than the old group (57/77 vs. 48/83, p<0.05). As the Table showed below, the young have statistically lower FPG, Cholesterol, LDL-C, Free Fatty Acid and better HOMA-B just after therapy (p<0.05). These results indicated that age might affect the remission rate mainly by the better improved metabolism of both glucose and lipids. Moreover, the results of HOMA-B has shown that younger will be easier to recover beta cell function.

 Young gruop at baseline Young gruop after therapy Old group at base line Old group after therapy 
FPG (mmol/L) 11.84±0.35 6.±0.13 11.79±0.36 6.73 ±0.18 
Cholesterol (mmol/L) 5.69 ±0.14 5.04 ±0.1 6.±0.13 5.73 ±0.12 
HDL-C (mmol/L) 1.±0.03 1.21 ±0.03 1.18 ±0.03 1.25 ±0.03 
LDL-C (mmol/L) 3.81 ±0.13 3.36 ±0.10 4.±0.13 3.87 ±0.10 
Free Fatty Acid (mEq/L) 0.59 ±0.02 0.50±0.03 0.68 ±0.05 0.61 ±0.04 
HOMA-β 22.37±1.77 75.02±6.62 25.13±2.26 56.38±3.85 
HOMA-IR 3.99 ±0.27 2.12 ±0.15 4.02 ±0.27 2.24 ±0.12 
 Young gruop at baseline Young gruop after therapy Old group at base line Old group after therapy 
FPG (mmol/L) 11.84±0.35 6.±0.13 11.79±0.36 6.73 ±0.18 
Cholesterol (mmol/L) 5.69 ±0.14 5.04 ±0.1 6.±0.13 5.73 ±0.12 
HDL-C (mmol/L) 1.±0.03 1.21 ±0.03 1.18 ±0.03 1.25 ±0.03 
LDL-C (mmol/L) 3.81 ±0.13 3.36 ±0.10 4.±0.13 3.87 ±0.10 
Free Fatty Acid (mEq/L) 0.59 ±0.02 0.50±0.03 0.68 ±0.05 0.61 ±0.04 
HOMA-β 22.37±1.77 75.02±6.62 25.13±2.26 56.38±3.85 
HOMA-IR 3.99 ±0.27 2.12 ±0.15 4.02 ±0.27 2.24 ±0.12 
View Large

Disclosure

X. Wan: None. Z. Huang: None. L. Xu: None. Y. Li: None.

© 2018 by the American Diabetes Association.
2018
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.